Clinical Takeaway
In this small pilot trial of 20 insomnia patients, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least in the short term, this cannabinoid combination did not improve objective sleep quantity. These findings highlight that patient-reported benefits of cannabis for sleep may not align with measurable EEG-based outcomes, and that dose, ratio, and formulation likely matter significantly when considering cannabinoids for insomnia management.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG characterization of how a standard THC/CBD formulation affects sleep architecture and cortical activity in patients with clinically diagnosed insomnia, addressing a critical gap in objective neurophysiological data that currently relies on subjective patient reports. The findings regarding next-day alertness and cognitive function are essential for determining whether cannabinoid sleep interventions carry risks of daytime impairment, a safety concern that must be quantified before recommending these agents as routine alternatives to FDA-approved sleep medications. These results will inform clinical decision-making about cannabinoid efficacy and tolerability in insomnia management and help establish parameters for larger controlled trials.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides valuable objective EEG data suggesting that a single dose of 10 mg THC with 200 mg CBD may improve sleep initiation and architecture in insomnia patients, yet several limitations warrant cautious interpretation before clinical adoption. The small sample size of 20 subjects, predominance of female participants, and single-dose design limit generalizability and our ability to assess tolerability with repeated use or in more diverse populations. Additionally, the study does not clarify the relative contributions of THC versus CBD, examine potential next-day cognitive or psychomotor effects in detail, or account for individual variation in cannabinoid metabolism and sensitivity, all of which significantly influence real-world outcomes. While the high-density EEG methodology is methodologically rigorous, a single night of improved sleep architecture does not necessarily translate to sustained benefit or predict long-term safety and efficacy. Clinically, these findings suggest that a THC/CBD combination warrants further investigation in larger, longer-duration trials before recommending it as